1
|
Aghbash PS, Hemmat N, Nahand JS, Shamekh A, Memar MY, Babaei A, Baghi HB. The role of Th17 cells in viral infections. Int Immunopharmacol 2021; 91:107331. [PMID: 33418239 DOI: 10.1016/j.intimp.2020.107331] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2020] [Revised: 12/19/2020] [Accepted: 12/20/2020] [Indexed: 02/07/2023]
Abstract
The present review provides an overview of recent advances regarding the function of Th17 cells and their produced cytokines in the progression of viral diseases. Viral infections alone do not lead to virus-induced malignancies, as both genetic and host safety factors are also involved in the occurrence of malignancies. Acquired immune responses, through the differentiation of Th17 cells, form the novel components of the Th17 cell pathway when reacting with viral infections all the way from the beginning to its final stages. As a result, instead of inducing the right immune responses, these events lead to the suppression of the immune system. In fact, the responses from Th17 cells during persistent viral infections causes chronic inflammation through the production of IL-17 and other cytokines which provide a favorable environment for tumor growth and its development. Additionally, during the past decade, these cells have been understood to be involved in tumor progression and metastasis. However, further research is required to understand Th17 cells' immune mechanisms in the vast variety of viral diseases. This review aims to determine the roles and effects of the immune system, especially Th17 cells, in the progression of viral diseases; which can be highly beneficial for the diagnosis and treatment of these infections.
Collapse
Affiliation(s)
- Parisa Shiri Aghbash
- Immunology Research Center, Tabriz University of Medical Sciences, ZIP Code 15731 Tabriz, Iran; Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, ZIP Code 15731 Tabriz, Iran
| | - Nima Hemmat
- Immunology Research Center, Tabriz University of Medical Sciences, ZIP Code 15731 Tabriz, Iran; Drug Applied Research Centre, Tabriz University of Medical Sciences, ZIP Code 15731 Tabriz, Iran
| | - Javid Sadri Nahand
- Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, ZIP Code 14155 Tehran, Iran; Student Research Committee, Iran University of Medical Sciences, ZIP Code 14155 Tehran, Iran
| | - Ali Shamekh
- Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, ZIP Code 15731 Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, ZIP Code 15731 Tabriz, Iran
| | - Mohammad Yousef Memar
- Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, ZIP Code 15731 Tabriz, Iran
| | - Abouzar Babaei
- Department of Virology, Faculty of Medicine, Tarbiat Modares University, ZIP Code 14155 Tehran, Iran
| | - Hossein Bannazadeh Baghi
- Immunology Research Center, Tabriz University of Medical Sciences, ZIP Code 15731 Tabriz, Iran; Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, ZIP Code 15731 Tabriz, Iran; Department of Virology, Faculty of Medicine, Tabriz University of Medical Sciences, ZIP Code 15731 Tabriz, Iran.
| |
Collapse
|
2
|
Korth J, Anastasiou OE, Verheyen J, Dickow J, Sertznig H, Frericks N, Bleekmann B, Kribben A, Brinkhoff A, Wilde B, Sutter K, Dittmer U, Ciesek S, Witzke O, Widera M. Impact of immune suppressive agents on the BK-Polyomavirus non coding control region. Antiviral Res 2018; 159:68-76. [PMID: 30268912 DOI: 10.1016/j.antiviral.2018.09.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Revised: 04/23/2018] [Accepted: 09/26/2018] [Indexed: 02/08/2023]
Abstract
BACKGROUND Reactivation of the BK-Polyomavirus (BKPyV) can cause a polyomavirus associated nephropathy in approx. 10% of kidney transplant recipients. In these cases, current therapy is based on the reduction of immunosuppression. Since BKPyV-transcription is driven by the Non-Coding-Control-Region (NCCR) we were interested whether NCCR-activity is affected by immunosuppressive agents. METHODS Plasma samples from 45 BKPyV-positive patients after renal transplantation were subjected to PCR-analysis. NCCR-amplicons were cloned into a plasmid that allows the quantification of early and late NCCR-activity by tdTomato and eGFP expression, respectively. HEK293T-cells were transfected with the reporter-plasmids, treated with immunosuppressive agents, and subjected to FACS-analysis. In addition, H727-cells were infected with patient derived BKPyV, treated with mTOR-inhibitors, and NCCR activity was analysed using qRT-PCR. RESULTS While tacrolimus and cyclosporine-A did not affect NCCR-promoter-activity, treatment with mTOR1-inhibitor rapamycin resulted in the reduction of early, but not late-NCCR-promoter-activity. Treatment with dual mTOR1/2 inhibitors (INK128 or pp242) led to significant inhibition of early, however, concomitantly enhanced late-promoter-activity. In BKPyV infected cells both rapamycin and INK128 reduced early expression, however, INK128 resulted in higher late-mRNA levels when compared to rapamycin treatment. CONCLUSIONS Our results demonstrate that mTOR1-inhibitors are able to reduce early-expression of wildtype and rearranged NCCRs, which might contribute to previously described inhibition of BKPyV-replication. Dual mTOR1/2-inhibitors, however, additionally might shift viral early into late-expression promoting synthesis of viral structural proteins and particle production.
Collapse
Affiliation(s)
- Johannes Korth
- Department of Nephrology, University of Duisburg-Essen, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany; Institute for Virology, University of Duisburg-Essen, University Hospital Essen, Virchowstr. 179, 45147, Essen, Germany
| | - Olympia E Anastasiou
- Institute for Virology, University of Duisburg-Essen, University Hospital Essen, Virchowstr. 179, 45147, Essen, Germany; Department of Gastroenterology, University of Duisburg-Essen, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany
| | - Jens Verheyen
- Institute for Virology, University of Duisburg-Essen, University Hospital Essen, Virchowstr. 179, 45147, Essen, Germany
| | - Julia Dickow
- Institute for Virology, University of Duisburg-Essen, University Hospital Essen, Virchowstr. 179, 45147, Essen, Germany
| | - Helene Sertznig
- Institute for Virology, University of Duisburg-Essen, University Hospital Essen, Virchowstr. 179, 45147, Essen, Germany
| | - Nicola Frericks
- Institute for Virology, University of Duisburg-Essen, University Hospital Essen, Virchowstr. 179, 45147, Essen, Germany
| | - Barbara Bleekmann
- Institute for Virology, University of Duisburg-Essen, University Hospital Essen, Virchowstr. 179, 45147, Essen, Germany
| | - Andreas Kribben
- Department of Nephrology, University of Duisburg-Essen, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany
| | - Alexandra Brinkhoff
- Department of Nephrology, University of Duisburg-Essen, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany
| | - Benjamin Wilde
- Department of Nephrology, University of Duisburg-Essen, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany
| | - Kathrin Sutter
- Institute for Virology, University of Duisburg-Essen, University Hospital Essen, Virchowstr. 179, 45147, Essen, Germany
| | - Ulf Dittmer
- Institute for Virology, University of Duisburg-Essen, University Hospital Essen, Virchowstr. 179, 45147, Essen, Germany
| | - Sandra Ciesek
- Institute for Virology, University of Duisburg-Essen, University Hospital Essen, Virchowstr. 179, 45147, Essen, Germany
| | - Oliver Witzke
- Department of Infectious Diseases, University of Duisburg-Essen, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany
| | - Marek Widera
- Institute for Virology, University of Duisburg-Essen, University Hospital Essen, Virchowstr. 179, 45147, Essen, Germany.
| |
Collapse
|
3
|
Kariminik A, Kheirkhah B. Tumor growth factor-β is an important factor for immunosuppression and tumorgenesis in Polyoma BK virus infection; a systematic review article. Cytokine 2017; 95:64-69. [PMID: 28237875 DOI: 10.1016/j.cyto.2017.02.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2017] [Revised: 02/07/2017] [Accepted: 02/12/2017] [Indexed: 02/07/2023]
Abstract
Polyoma BK virus (PBK) is a prevalent human specific virus and the cause of several malignancies in human. The main mechanisms used by PBK to induce/stimulate human cancers are yet to be clarified but it has been proposed that PBK may use several mechanisms to induce/stimulate cancers in human including attenuation of immune responses via up-regulation of immunosuppressor molecules. Transforming growth factor beta (TGF-β) is a key multifunctional factor from modulation of immunosurveillance to angiogenesis. The key roles of TGF-β in the progression of Th17 and T regulatory subsets, the most important immune cells involved in development of cancers, have been demonstrated. Thus, this review article aims to describe the mechanisms used by PBK in induction/stimulation of human cancers in TGF-β dependent manner..
Collapse
Affiliation(s)
- Ashraf Kariminik
- Department of Microbiology, Kerman Branch, Islamic Azad University, Kerman, Iran.
| | - Babak Kheirkhah
- Department of Microbiology, Kerman Branch, Islamic Azad University, Kerman, Iran
| |
Collapse
|
4
|
Urayama T, Takahashi K, Ideno S, Yunoki M, Saito M, Numakura K, Inoue T, Satoh S, Sakai K. BK polyomavirus‐neutralizing activity of intravenous immunoglobulin products derived from donated blood in Japan. ACTA ACUST UNITED AC 2016. [DOI: 10.1111/voxs.12294] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- T. Urayama
- Research and Development Division Japan Blood Products Organization Hyogo Japan
| | - K. Takahashi
- Research and Development Division Japan Blood Products Organization Hyogo Japan
| | - S. Ideno
- Research and Development Division Japan Blood Products Organization Hyogo Japan
| | - M. Yunoki
- Research and Development Division Japan Blood Products Organization Hyogo Japan
| | - M. Saito
- Department of Urology Akita University Graduate School of Medicine Akita Japan
| | - K. Numakura
- Department of Urology Akita University Graduate School of Medicine Akita Japan
| | - T. Inoue
- Department of Urology Akita University Graduate School of Medicine Akita Japan
| | - S. Satoh
- Center for Kidney Disease and Transplantation Akita University Hospital Akita Japan
| | - K. Sakai
- Research and Development Division Japan Blood Products Organization Hyogo Japan
| |
Collapse
|